# US 2024/0189274 A1 · Compositions And Methods For The Treatment Of Depression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189274 A1
- Document ID: US20240189274A1
- Status: Published application
- Kind: A1
- Application number: 18/428,937
- Filed: 2024-01-31
- Published: 2024-06-13
- Earliest claimed: 2021-05-04
- Assignees: Janssen Pharmaceuticals, Inc.
- Applicants: Janssen Pharmaceuticals, Inc.
- Inventors: Mark Schmidt; Vanina Popova; Adam Savitz; Rama Melkote; Wayne C. Drevets; Srihari Gopal; Darrel Pemberton; Chakradhar Lagishetty; Iva Kezic
- Web page: https://patentgrep.com/patent/US20240189274A1

## CPC

- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61P 25/24: Antidepressants
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

## Claims

### Claim 1

A method for treating major depressive disorder in a human patient, comprising administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof, wherein the patient had an inadequate response to other antidepressant therapy prior to treatment with the aticaprant, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the other antidepressant therapy comprised one or more antidepressants.

### Claim 3 (depends on 2)

The method of claim 2, wherein the one or more antidepressants of the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, further comprising treatment with an effective amount of one or more antidepressants.

### Claim 5 (depends on 4)

The method of claim 4, wherein the one or more antidepressants is a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the aticaprant is S-aticaprant, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the effective amount of the aticaprant is about 2 to about 35 mg.

### Claim 8 (depends on 7)

The method of claim 7, wherein the effective amount of the aticaprant is about 10 mg.

### Claim 9 (depends on 1)

The method of claim 1, wherein the aticaprant, or a pharmaceutically acceptable salt thereof, is administered orally.

### Claim 10 (depends on 1)

The method of claim 1, wherein the aticaprant, or a pharmaceutically acceptable salt thereof, is administered once daily.

### Claim 11

A method for treating major depressive disorder in a human patient, comprising administering to the patient in need thereof about 10 mg of aticaprant orally and once daily, wherein the patient had an inadequate response to other antidepressant therapy prior to treatment with the aticaprant.

### Claim 12 (depends on 11)

The method of claim 11, further comprising treatment with an effective amount of one or more antidepressants.

### Claim 13 (depends on 12)

The method of claim 12, wherein the one or more antidepressants is a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

### Claim 14 (depends on 11)

The method of claim 11, wherein the other antidepressant therapy comprised one or more antidepressants.

### Claim 15 (depends on 14)

The method of claim 14, wherein the one or more antidepressants of the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

### Claim 16 (depends on 11)

The method of claim 11, wherein the aticaprant is S-aticaprant.

### Claim 17 (depends on 13)

The method of claim 13, wherein the other antidepressant therapy comprised one or more antidepressants.

### Claim 18 (depends on 17)

The method of claim 17, wherein the one or more antidepressants of the other antidepressant therapy is a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the aticaprant is S-aticaprant.
